{"analyses":[{"ciLowerLimit":"0.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.64","estimateComment":"IPTW HRs were estimated using weighted Cox proportional hazard models and confidence intervals were estimated using robust error variances.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":".0003","paramType":"Hazard Ratio (HR)","paramValue":"0.37","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI was not estimated because of insufficient number of participants with the event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"3.25","upperLimit":"6.28","value":"5.26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"235"}],"units":"Participants"}],"description":"PFS: a) C1071003 Cohort A: time from the date of the first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first; b) COTA: time from initiation of the first line after participant identified as having TCR MM to either the date of progression or death due to any cause, whichever occurred first. IMWG criteria for progression: an increase of \\>=25% from the lowest response value in any 1 or more of the criteria: SPEP with an absolute increase \\>0.5 g/dL; 24-hour UPEP with an absolute increase \\>200 mg/24 h; in participants without measurable serum and urine M-protein, the absolute increase of \\>10 mg/dL in the difference between involved and uninvolved FLC levels; or an absolute bone marrow plasma cell percentage \\>10%. Retrospective data was retrieved and observed in the current study for approximately 1.5 months. Participants without an event were censored at date of last adequate disease assessment or the data cut-off. Kaplan Meier method was used.","dispersionType":"95% Confidence Interval","groups":[{"description":"Eligible participants with TCR MM, who were BCMA naïve, who were enrolled between 2 February 2021 to 07 January 2022 and who were treated with elranatamab in study C1071003 were included.","id":"OG000","title":"C1071003 Cohort A"},{"description":"Eligible participants with TCR MM who were treated with SOC therapies in real world clinical practice setting, identified from COTA database were included. This arm served as external control arm.","id":"OG001","title":"RWD: COTA"}],"paramType":"MEDIAN","populationDescription":"Eligible participants whose data was retrieved and was used in this retrospective cohort study. In this outcome measure, IPTW analysis was applied. IPTW eliminated the effect of confounding by observed baseline participant characteristics, improve covariate balance, and thereby obtained unbiased estimates of treatment effects. IPTW created pseudo-sets, hence \"Number of Participants Analyzed\" (N) are different from participant flow and baseline section.","reportingStatus":"POSTED","timeFrame":"C1071003:First dose to confirmed PD/ death due to any cause or censoring whichever occurred first (maximum of 15 months);COTA:Initiation of first line post TCR MM to PD/ death due to any cause or censoring whichever occurred first (maximum of 64.3 months)","title":"PFS: C1071003 Cohort A Versus COTA Cohort- Using Inverse Probability of Treatment Weights (IPTW)","type":"PRIMARY","unitOfMeasure":"Months"}